Patents Assigned to UNIVERSITATSSPITAL BASEL
  • Patent number: 11801256
    Abstract: A method of enhancing positive effects of a psychedelic, by pretreating an individual with an antidepressant, administering a psychedelic to the individual, and inducing a more positive psychological state in the individual with the antidepressant-psychedelic combination compared with the psychedelic alone. A method of enhancing positive effects of a psychedelic, by inhibiting serotonin transport in an individual, increasing levels of endogenous monoamines in the individual, and stimulating 5-HT2A receptors in the individual. A composition including an antidepressant and a psychedelic in the same dosage form.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: October 31, 2023
    Assignee: Universitätsspital Basel
    Inventors: Matthias Emanuel Liechti, Anna Margarete Becker
  • Publication number: 20230330085
    Abstract: Method of dosing and treating patients with a psychedelic, by administering a psychedelic at a dose of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, and producing maximum positive subjective acute effects that are known to be associated with more positive long-term outcomes and minimizing negative acute effects. Method of determining a dose of a psychedelic for an individual, by administering a dose of a psychedelic to the individual of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual. Methods of treating psychiatric conditions or providing therapy. Method of defining therapeutic doses of a psychedelic in clinical trials. Method of monitoring individuals for depression after treatment with LSD.
    Type: Application
    Filed: June 16, 2023
    Publication date: October 19, 2023
    Applicant: Universitatsspital Basel
    Inventors: Matthias Emanuel LIECHTI, Friederike Sophie HOLZE
  • Publication number: 20230285384
    Abstract: A method of dosing LSD in treating patients, by assessing genetic characteristics in the patient by identifying polymorphisms of CYP2D6 before use of a composition chosen from the group consisting of LSD, analogs thereof, derivatives thereof, and salts thereof, administering the composition to the patient based on the patient genetics, wherein a 50% dose is administered in a patient with non-functional CYP2D6 compared to a dose in functional CYP2D6 individuals, and producing maximum positive subjective acute effects in the patient and/or reducing anxiety and negative effects. A method of determining a preferred dose of LSD.
    Type: Application
    Filed: May 22, 2023
    Publication date: September 14, 2023
    Applicant: Universitatsspital Basel
    Inventors: Matthias Emanuel LIECHTI, Patrick Raphael VIZELI
  • Patent number: 11717517
    Abstract: A method of dosing and treating patients with a psychedelic, by administering a psychedelic at a dose of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, and producing maximum positive subjective acute effects that are known to be associated with more positive long-term outcomes and minimizing negative acute effects. A method of determining a dose of a psychedelic for an individual, by administering a dose of a psychedelic to the individual of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual. Methods of treating psychiatric conditions or providing therapy. A method of defining therapeutic doses of a psychedelic in clinical trials.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: August 8, 2023
    Assignee: Universitatsspital Basel
    Inventors: Matthias Emanuel Liechti, Friederike Sophie Holze
  • Publication number: 20230218568
    Abstract: A composition including R-MDMA, S-MDMA, or specific (not 1:1 as in racemic MDMA) combinations of these two enantiomers of racemic MDMA as well as R-MDA, S-MDA, and a combination that is not 1:1 of R-MDA and S-MDA. A method of treating an individual, especially in substance-assisted psychotherapy by administering the composition to the individual. A method of personalized medicine, by evaluating an individual who is in need of MDMA treatment and determining if there are characteristics of the individual present that would not be suitable for MDMA treatment, and administering the composition to the individual. A method of reducing abuse of MDMA by an individual, by administering R-MDMA to the individual and thereby reducing abuse.
    Type: Application
    Filed: December 14, 2022
    Publication date: July 13, 2023
    Applicant: UNIVERSITATSSPITAL BASEL
    Inventor: Matthias Emanuel LIECHTI
  • Publication number: 20230201160
    Abstract: A method of enhancing positive effects of a psychedelic, by inducing a positive psychological state in an individual with an empathogen/entactogen, administering a psychedelic to the individual, and enhancing a positive response to the psychedelic. A composition including an entactogen/empathogen and a serotonergic psychedelic in the same dosage form or administered as separate compositions within a combination treatment schedule. A method of enhancing positive effects of a psychedelic, by inducing the release of endogenous monoamines, and subsequently stimulating 5-HT2A receptors.
    Type: Application
    Filed: March 6, 2023
    Publication date: June 29, 2023
    Applicant: UNIVERSITATSSPITAL BASEL
    Inventor: Matthias Emanuel LIECHTI
  • Patent number: 11648103
    Abstract: The invention relates to an artificial vascular graft comprising a primary scaffold structure encompassing an inner space of the artificial vascular graft, said primary scaffold structure having an inner surface facing towards said inner space and an outer surface facing away from said inner space, a coating on said inner surface, wherein a plurality of grooves is comprised in said coating of said inner surface. The primary scaffold structure comprises further a coating on said outer surface. The primary scaffold structure and the coating on said inner surface and on said outer surface are d designed in such a way that cells, in particular progenitor cells, can migrate from the periphery of said artificial vascular graft through said outer surface of said coating, said primary scaffold structure and said inner surface to said inner space, if the artificial vascular graft is used as intended. The invention relates further to a method for providing said graft.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: May 16, 2023
    Assignee: UNIVERSITÄTSSPITAL BASEL
    Inventors: Bernhard Winkler, Martin Grapow, Friedrich Eckstein, Aldo Ferrari, Dimos Poulikakos, Simone Bottan, Maximilian Fischer, Tobias Lendenmann
  • Publication number: 20230039395
    Abstract: A method of treating a patient with a psychedelic, by administering either a dose of LSD to the patient that is equivalent to a known dose of psilocybin with desired acute and therapeutic effects, or administering a dose of psilocybin to the patient that is equivalent to a known dose of LSD with desired acute and therapeutic effects. A method of treating a patient with LSD, by administering a dose of LSD to the patient equivalent to those of psilocybin known to be associated with positive long-term therapeutic outcomes. A method of determining a dose of a psychedelic or the dose-equivalence to another psychedelic to be administered to an individual, by administering a dose of a psychedelic to an individual, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual.
    Type: Application
    Filed: May 2, 2022
    Publication date: February 9, 2023
    Applicant: Universitätsspital Basel
    Inventors: Matthias Emanuel LIECHTI, Friederike Sophie HOLZE
  • Publication number: 20230000799
    Abstract: A method of inducing psychedelic states in an individual, by administering mescaline, a salt thereof, analogs thereof, or derivatives thereof to the individual, and inducing a psychedelic state in the individual. A method of therapy, by administering an intermediate “good effect dose” of mescaline, salt of mescaline, analogs thereof, or derivatives thereof to an individual, and inducing positive acute drug effects that are known to be associated with more positive long-term responses in psychiatric patients. A method of therapy, by administering an “ego-dissolution” dose of mescaline, a salt of mescaline, analogs thereof, or derivatives thereof to an individual, and providing the experience of ego-dissolution.
    Type: Application
    Filed: August 8, 2022
    Publication date: January 5, 2023
    Applicant: Universitätsspital Basel
    Inventor: Matthias Emanuel LIECHTI
  • Publication number: 20220387456
    Abstract: A method of enhancing positive effects of a psychedelic, by pretreating an individual with an antidepressant, administering a psychedelic to the individual, and inducing a more positive psychological state in the individual with the antidepressant-psychedelic combination compared with the psychedelic alone. A method of enhancing positive effects of a psychedelic, by inhibiting serotonin transport in an individual, increasing levels of endogenous monoamines in the individual, and stimulating 5-HT2A receptors in the individual. A composition including an antidepressant and a psychedelic in the same dosage form.
    Type: Application
    Filed: March 10, 2022
    Publication date: December 8, 2022
    Applicant: Universitätsspital Basel
    Inventors: Matthias Emanuel LIECHTI, Anna Margarete BECKER
  • Publication number: 20220347169
    Abstract: A method of dosing LSD in treating patients, by assessing genetic characteristics in the patient by identifying polymorphisms of CYP2D6 before use of a composition chosen from the group consisting of LSD, analogs thereof, derivatives thereof, and salts thereof, administering the composition to the patient based on the patient genetics, wherein a 50% dose is administered in a patient with non-functional CYP2D6 compared to a dose in functional CYP2D6 individuals, and producing maximum positive subjective acute effects in the patient and/or reducing anxiety and negative effects. A method of determining a preferred dose of LSD.
    Type: Application
    Filed: July 21, 2022
    Publication date: November 3, 2022
    Applicant: Universitätsspital Basel
    Inventors: Matthias Emanuel LIECHTI, Patrick Raphael VIZELI
  • Publication number: 20220323405
    Abstract: A composition for treating an individual while reducing acute adverse effects of an empathogen/entactogen, including effective amounts of the empathogen/entactogen and an adverse effect-reducing agent that blocks adverse effects of the empathogen/entactogen. A method of treating an individual with an empathogen/entactogen and reducing its acute adverse effects, by administering an empathogen/entactogen to the individual, administering an adverse effect-reducing agent to the individual, and reducing the acute adverse effects of the empathogen/entactogen. A method of stopping the acute cardiostimulant and hyperthermic action of an empathogen/entactogen in an individual, by administering an adverse effect-reducing agent to the individual after the individual has taken the empathogen/entactogen and stopping the acute adverse effects of the empathogen/entactogen. A method of treating an individual at risk of cardiovascular events and/or hyperthermia with an empathogen/entactogen.
    Type: Application
    Filed: March 10, 2022
    Publication date: October 13, 2022
    Applicant: Universitätsspital Basel
    Inventor: Matthias Emanuel LIECHTI
  • Publication number: 20220280501
    Abstract: A method of dosing LSD in treating patients, by assessing genetic characteristics in the patient before LSD use, administering LSD to the patient based on the patient genetics, and producing maximum positive subjective acute effects in the subject and/or reducing anxiety and negative effects. A method of determining a preferred dose of LSD, by determining metabolic and genetic markers in a patient (such as by assessing CYP2D6 activity and/or assessing 5HTR1A rs6295 and 5HTR2A rs6313 genotypes in a patient), adjusting a dose of LSD based on the metabolic activity and genetic profile, administering the dose of LSD to the patient, and producing maximum positive subjective acute effects in the subject and/or reducing anxiety and negative effects. A method of determining a dose of LSD based on an assessment of the presence of CYP2D6 inhibitors.
    Type: Application
    Filed: March 2, 2022
    Publication date: September 8, 2022
    Applicant: Universitätsspital Basel
    Inventors: Matthias Emanuel LIECHTI, Patrick Raphael VIZELI
  • Publication number: 20220273628
    Abstract: A method of treating anxiety disorders specifically not associated with causes such as a life-threatening serious somatic illness, by administering a psychedelic to an individual, and treating anxiety and specifically causing reductions in the rating scale score measures of anxiety (STAI global or state or trait anxiety) and/or measures of depression (HDRS or BDI scores) and/or measures of general psychological distress (SCL-90 ratings) in the patient for several weeks beyond administration of the psychedelic. A method of treating anxiety, by administering a psychedelic (preferably LSD) to an individual having anxiety not associated with causes such as a life-threatening serious somatic illness, and inducing positive acute drug effects and positive long-term therapeutic effects in the individual.
    Type: Application
    Filed: February 15, 2022
    Publication date: September 1, 2022
    Applicant: Universitätsspital Basel
    Inventors: Matthias Emanuel LIECHTI, Friederike Sophie HOLZE
  • Publication number: 20220265582
    Abstract: A method of inducing psychedelic states in an individual, by administering mescaline, a salt thereof, analogs thereof, or derivatives thereof to the individual, and inducing a psychedelic state in the individual. A method of therapy, by administering an intermediate “good effect dose” of mescaline, salt of mescaline, analogs thereof, or derivatives thereof to an individual, and inducing positive acute drug effects that are known to be associated with more positive long-term responses in psychiatric patients. A method of therapy, by administering an “ego-dissolution” dose of mescaline, a salt of mescaline, analogs thereof, or derivatives thereof to an individual, and providing the experience of ego-dissolution.
    Type: Application
    Filed: February 18, 2022
    Publication date: August 25, 2022
    Applicant: Universitätsspital Basel
    Inventor: Matthias Emanuel LIECHTI
  • Patent number: 11389640
    Abstract: The present invention relates to systems, methods and algorithms for determination of heart pump function and their use in livings subject are described. The invention further relates to complementary parts of such systems that work best in combination. Medical catheters, sheaths and shafts are disclosed that carry an arrangement of integrated digital sensor systems-on-chip (SoC) in the portion thereof residing inside the body. These devices combine at their portion that resides inside the body, the complete chain of signal transduction, signal analog-to-digital conversion and digital signal transmission, and allow to acquire single and multiple physical entities in a single setup. In specific instances the devices integrate wireless data transfer functionality, and in specific instances they integrate wireless energy harvesting for battery-free functionality.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: July 19, 2022
    Assignees: HighDim GmbH, Universitätsspital Basel
    Inventors: Oleksii Morozov, Patrick Hunziker
  • Patent number: 11364221
    Abstract: A method of enhancing positive therapeutic effects of a psychedelic, by inducing a positive psychological state in an individual with an empathogen/entactogen of MDMA administered in a dose of 20-200 mg, administering a psychedelic to the individual, and enhancing a positive response to the psychedelic. A composition including an entactogen/empathogen and a psychedelic in the same dosage form.
    Type: Grant
    Filed: December 13, 2021
    Date of Patent: June 21, 2022
    Assignee: Universitätsspital Basel
    Inventor: Matthias Emanuel Liechti
  • Publication number: 20220088144
    Abstract: The present invention relates to the use of SGLT-2 inhibitors and/or an interleukin-1-receptor antagonist or a non-agonist antibody reactive to IL-1 or IL-1R in the treatment of prevention of symptomatic hypoglycaemia after bariatric surgery.
    Type: Application
    Filed: January 13, 2020
    Publication date: March 24, 2022
    Applicant: UNIVERSITÄTSSPITAL BASEL
    Inventor: Marc DONATH
  • Patent number: 11033642
    Abstract: The invention relates to octadentate ligands of a general formula R1-D-X-D-X-D-X-D-E-R2, wherein D is C(O)N(OH) or N(OH)C(O), pyrimidinone or pyridinone, each X independently of any other X is a saturated or partially unsaturated, substituted or unsubstituted linker comprising 8-11 atoms selected from any of N, C, O; R1 is alkyl, cycloalkyl, arene, or heteroarene, E is a saturated or partially unsaturated, substituted or unsubstituted chain comprising 1-50 atoms and R2 is a moiety capable of selectively binding to a biomolecule, or a nanoparticle. The invention further relates to complexes of the ligand, particularly radionuclides and their use in radioimmunotherapy and imaging.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: June 15, 2021
    Assignees: UNIVERSITAT ZURICH, UNIVERSITATSSPITAL BASEL
    Inventors: Malay Patra, Gilles Gasser, Thomas L. Mindt, Andreas Bauman
  • Patent number: 10588962
    Abstract: The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: March 17, 2020
    Assignees: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., UNIVERSITÄTSSPITAL BASEL
    Inventors: Peter H. Seeberger, Pierre Stallforth, Gennaro De Libero, Marco Cavallari